Sort
21,453 grants matching “tuberculosis”
MYCOBACTERIUM TUBERCULOSIS PROTEOME-WIDE EPITOPE DISCOVERY AND HOST TRANSCRIPTOME-WIDE T CELL PHENOTYPING IN HIGH DISEASE BURDEN POPULATIONS
$1,504,937John Altin · Translational Genomics Research Inst · N01 · FY2024 · AI
Childhood âOmicsâ and Mycobacterium tuberculosis-derived BiOsignatures (COMBO) for TB diagnosis in high HIV prevalence settings
$1,503,586Adithya Cattamanchi · University Of California, San Francisco · R01 · FY2020 · AI
MIAMI ADULT AIDS CLINICAL TRIALS GROUP, AACTG
$1,501,740University Of Miami School Of Medicine · U01 · FY2003 · AI
Baylor-UTHouston Center for AIDS Research
$1,500,497Janet S Butel · Baylor College Of Medicine · P30 · FY2006 · AI
Evaluation of new diagnostics for incident, active and recurrent TB (ENDx-Tb)
$1,500,000Gerhard Walzl · Stellenbosch University · U01 · FY2021 · AI
Capturing spatial patterns of new M. tuberculosis infection in Kampala, Uganda
$1,500,000Charles Martyn Bark · Case Western Reserve University · R01 · FY2023 · AI
Regional Prospective Observational Research in Tuberculosis (RePORT) International Coordinating Center (RICC) (RePORT RICC)
$1,500,000Michael Dignam · National Institute Of Allergy And Infectious Diseases · Y01 · FY2018 · AI
Evaluation of new diagnostics for incident, active and recurrent TB (ENDx-Tb)
$1,500,000Gerhard Walzl · Stellenbosch University · U01 · FY2024 · AI
CENTER FOR AIDS RESEARCH(CFAR)
$1,500,000Case Western Reserve University · P30 · FY2004 · AI
Evaluation of new diagnostics for incident, active and recurrent TB (ENDx-Tb)
$1,500,000Gerhard Walzl · Stellenbosch University · U01 · FY2023 · AI
RAPID POINT OF CARE TESTS FOR TUBERCULOSIS
$1,500,000Yan Zhou · Zymeron Corporation · N44 · FY2021 · AI
Dev & Testing of New Medications for Treatment of Emerging Infectious Diseases
$1,500,000Mitchell Allen Avery · University Of Mississippi · U01 · FY2006 · CI
DAIDS RePORT India Consortium
$1,500,000National Institute Of Allergy And Infectious Diseases · Y01 · FY2017 · AI
Evaluation of new diagnostics for incident, active and recurrent TB (ENDx-Tb)
$1,500,000Gerhard Walzl · Stellenbosch University · U01 · FY2020 · AI
RePORT South Africa
$1,500,000National Institute Of Allergy And Infectious Diseases · Y01 · FY2016 · AI
TUBERCULOSIS PREVENTION RESEARCH UNIT
$1,500,000Case Western Reserve University · N01 · FY2000 · AI
INNOVATIVE PEDIATRIC ORAL FORMULATIONS FOR SECOND LINE TUBERCULOSIS DRUGS
$1,499,998Nikolai Braun · Luna Innovations, Inc. · N44 · FY2021 · AI
Innovative Oral Formulations for Anti-Tb Drugs
$1,499,796Luna Innovations, Inc. · N01 · FY2018 · AI
Fox COBRE Phase II Admin Core
$1,498,202Joseph M Fox · University Of Delaware · P20 · FY2023 · GM
MYCOBACTERIUM TUBERCULOSIS (MTB) QUALITY ASSESSMENT PROGRAM (TBQA)
$1,497,671Jeanette Coffin · Midwest Research Institute · N01 · FY2021 · AI
Membrane Protein Structural Genomics: M. tuberculosis
$1,495,936Florida State University · P01 · FY2003 · GM
Stellenbosch University Clinical Trials Unit
$1,495,502Anneke Catharina Hesseling · Stellenbosch University · UM1 · FY2025 · AI
Baylor-UTHouston Center for AIDS Research
$1,493,692Baylor College Of Medicine · P30 · FY2005 · AI
Facility Management, Maintenance and Operation Core
$1,493,669Raymond Paul Goodrich · Colorado State University · UC7 · FY2024 · AI
Lactoferrin as an Adjuvant for Cellular Immunity
$1,493,024Jeffrey K Actor · Pharmareview Corporation · R42 · FY2009 · AI